Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids [PDF]
Respiratory Research, 2021 Background For patients with chronic obstructive pulmonary disease (COPD), greater improvements in lung function have been demonstrated for triple versus dual inhaled therapies in traditional spirometry studies. This study was the first to use functional
Maarten van den Berge +7 more
doaj +6 more sources
Equivalência farmacêutica da formulação combinada de budesonida e formoterol em cápsula única com dispositivo inalador de pó Pharmaceutical equivalence of the combination formulation of budesonide and formoterol in a single capsule with a dry powder inhaler [PDF]
Jornal Brasileiro de Pneumologia, 2012 OBJETIVO: Avaliar a equivalência farmacêutica da formulação teste (associação fixa de budesonida e fumarato de formoterol em cápsula única dispensada com o dispositivo Aerocaps®) em relação a uma formulação referência (budesonida e fumarato de formoterol
Marina Andrade-Lima +2 more
doaj +5 more sources
Effect of inhaled budesonide/formoterol fumarate dihydrate delivered via two different devices on lung function in patients with COPD and low peak inspiratory flow [PDF]
Therapeutic Advances in Respiratory Disease, 2022 Background and aims: Low peak inspiratory flow (PIF) is common following severe exacerbations of chronic obstructive pulmonary disease (COPD). Patients with COPD and low PIF may be at risk of suboptimal delivery of inhaled therapies to the airways ...
Bärbel Huber +4 more
doaj +2 more sources
Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study [PDF]
BMC Pulmonary Medicine, 2011 Background The inhaled corticosteroid (ICS) fluticasone propionate (fluticasone) and the long-acting β2-agonist (LABA) formoterol fumarate (formoterol) are being made available as a combination product (fluticasone/formoterol, flutiform®) in a single ...
McAulay Kirsten +3 more
doaj +4 more sources
Successful Sequential Treatment for Severe Asthma Coexisting COVID-19 via Budesonide/Glycopyrrolate/Formoterol Fumarate [PDF]
International Journal of General Medicine, 2021 Yingjian Liang,* Meizhu Chen,* Cuiyan Tan, Changli Tu, Xiaobin Zheng, Jing Liu Department of Pulmonary and Critical Care Medicine (PCCM), The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, People’s Republic of China*These authors ...
Liang Y +5 more
doaj +2 more sources
Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study [PDF]
International Journal of COPD, 2022 Enrico de Nigris,1 Catrin Treharne,2 Nick Brighton,2 Ulf Holmgren,3 Andrew Walker,4 John Haughney5 1Formerly of Global Product and Portfolio Strategy, AstraZeneca, Cambridge, UK; 2Formerly of Health Economic Modelling, Regulatory and Access, Parexel ...
de Nigris E +5 more
doaj +2 more sources
Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler dual therapies in patients with COPD: a sub-study of the ETHOS trial [PDF]
Therapeutic Advances in Respiratory Disease, 2021 Background: In the phase III, 52-week ETHOS study in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF), at two inhaled corticosteroid dose levels ...
Klaus F. Rabe +7 more
doaj +2 more sources
Effect of budesonide/glycopyrronium/formoterol fumarate dihydrate on cardiopulmonary outcomes in COPD: rationale and design of the THARROS trial [PDF]
ERJ Open ResearchBackground COPD and cardiovascular disease (CVD) are leading causes of death with overlapping and syndemic pathophysiological interactions. Inhaled triple therapies containing inhaled corticosteroids (ICS), long-acting muscarinic antagonists (LAMA) and ...
Fernando J. Martinez +14 more
doaj +2 more sources
Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS [PDF]
International Journal of COPDShigeo Muro,1 Munehiro Seki,2 John R Hurst,3 David Petullo,4 Jonathan Marshall,5 Karin Bowen,4 Patrick F Darken,4 Elizabeth A Duncan,6 Ayman Megally,4 Mehul Patel5 1Department of Respiratory Medicine, Nara Medical University, Nara, Japan; 2AstraZeneca K ...
Muro S +9 more
doaj +2 more sources
Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma [PDF]
Pharmacology Research & Perspectives, 2022 The single‐inhaler extrafine formulation triple combination beclometasone dipropionate (BDP), formoterol fumarate (FF) plus glycopyrronium bromide (GB) is available for asthma management in adults. Its use in adolescents has not yet been evaluated.
Piotr Kuna +7 more
doaj +2 more sources